

To: [redacted] 5.1.2e [redacted] 5.1.2e @charite.de]
Cc: [redacted] 5.1.2e [redacted] 5.1.2e @erasmusmc.nl]; [redacted] 5.1.2e [redacted] 5.1.2e @charite.de]; [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl]; [redacted] 5.1.2e [redacted] 5.1.2e @ecdc.europa.eu]; [redacted] 5.1.2e [redacted] 5.1.2e @ecdc.europa.eu]
From: [redacted] 5.1.2e
Sent: Fri 1/10/2020 7:26:26 AM
Subject: Re: [ext] !!!! proposal text for initial lab response to novel cov evd-labnet. Please respond.
Received: Fri 1/10/2020 7:26:35 AM

Hi [redacted] 5.1.2e

That is true, but we speculate right now and when reviewing ALL SARS-like viruses, these and the pancorona's come up as best (or least worst), although as you rightfully point out there are some outliers there as well. Of course we need to get the sequence, but one way could be [redacted] 5.1.2a

[redacted] 5.1.2a

Last night we sent around an analysis to that end, to [redacted] 5.1.2e I will resend it to you

[redacted] 5.1.2e

On 10 Jan 2020, at 01:33, [redacted] 5.1.2e <[redacted] 5.1.2e @charite.de> wrote:

Hi [redacted] 5.1.2e

sorry for my late response. I cross-checked your suggestion, to use the Kuiken et N-assay published in Lancet 2003.

I would be very careful recommending this assay!

This assay shows some critical mismatches against some SARS-related viruses from China, and even more against the conspecific SARS-related viruses from European/African bats.

See attached an alignment (based on all SARS-related CoV from GenBank, condensed to divergent seq. in the target region)

Best [redacted] 5.1.2e

--

[redacted] 5.1.2e

Charite - Universitätsmedizin Berlin
 Campus Charite Mitte
 Chariteplatz 1
 D-10117 Berlin, Germany

Tel. +49 30 450 625 095

Fax +49 30 450 752 5907

E-Mail: [redacted] 5.1.2e @charite.de

[redacted] 5.1.2e

<http://virologie-ccm.charite.de/>

Von: [redacted] 5.1.2e <[redacted] 5.1.2e @erasmusmc.nl>

Gesendet: Donnerstag, 9. Januar 2020 15:34

An: [redacted] 5.1.2e <[redacted] 5.1.2e @charite.de>; [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e

[redacted] 5.1.2e <[redacted] 5.1.2e @charite.de>; [redacted] 5.1.2e <[redacted] 5.1.2e @erasmusmc.nl>; [redacted] 5.1.2e

<[redacted] 5.1.2e @ecdc.europa.eu>; [redacted] 5.1.2e <[redacted] 5.1.2e @ecdc.europa.eu>

Betreff: Re: [ext] !!!! proposal text for initial lab response to novel cov evd-labnet. Please respond.

Fine with me as well.

Actually, the SARS CoV taqman we used in 2003 should also (most likely) detect this virus as it targets conserved part of the nucleocapsid. But this needs to be confirmed once we get a sequence....Would be urgent to confirm this asap!

5.1.2e

Van: 5.1.2e <5.1.2e@charite.de>

Verzonden: donderdag 9 januari 2020 15:25:11

Aan: 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e

Onderwerp: Re: [ext] !!!! proposal text for initial lab response to novel cov evd-labnet. Please respond.

Hi 5.1.2e, you could specify "SARS-like viruses" as the "subgenus Sarbecovirus" to adhere to latest taxonomy. Everything else is fine.

5.1.2e

5.1.2e
5.1.2e

Charité - Universitätsmedizin Berlin
Campus Charité Mitte

Chariteplatz 1
D-10117 Berlin
Germany

E-Mail: 5.1.2e@charite.de

5.1.2e

<https://globalhealth.charite.de/>



Dubbel

3 - 3

Dubbel